The biotech has nominated MB-111, a drug it's developing as a treatment for elevated triglycerides, as its first clinical development candidate.

DCx sees potential to build multifunctional ADCs using the same technology Repare used to create its small molecule synthetic lethal therapies.

The firm is studying the combination in the first-line setting for head and neck cancer patients who had a PD-L1 combined positive score of less than 1.

Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

A trial by MSK researchers has shown that neoadjuvant treatment with GSK's Jemperli spared 80 percent of patients with dMMR ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

NEW YORK – Caring Cross announced Thursday it is partnering with the Wellbeing Foundation Africa to increase access to CAR-T cell therapies and stem cell gene therapies in Nigeria. Through the ...

DCx will gain rights to technology, targets, and preclinical programs from Repare along with lab space and staff in Montreal.

The firm enrolled the first patient at Florida's BayCare Morton Plant Hospital, and the study procedure went according to protocol, per an investigator.